Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes (Q44990830)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

8 December 2017

Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes (English)

1 reference

Europe PubMed Central

8 December 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

8 December 2017

author name string

M H Tan

1

1 reference

Europe PubMed Central

8 December 2017

D Johns

2

1 reference

Europe PubMed Central

8 December 2017

J Strand

3

1 reference

Europe PubMed Central

8 December 2017

J Halse

4

1 reference

Europe PubMed Central

8 December 2017

J W Eriksson

6

1 reference

Europe PubMed Central

8 December 2017

J Clausen

7

1 reference

Europe PubMed Central

8 December 2017

C S Konkoy

8

1 reference

Europe PubMed Central

8 December 2017

M Herz

9

1 reference

Europe PubMed Central

8 December 2017

GLAC Study Group

10

1 reference

Europe PubMed Central

8 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 August 2004

1 reference

Europe PubMed Central

8 December 2017

Diabetic Medicine

1 reference

Europe PubMed Central

8 December 2017

21

1 reference

Europe PubMed Central

8 December 2017

859-866

1 reference

Europe PubMed Central

8 December 2017

8

1 reference

Europe PubMed Central

8 December 2017

Combining sulfonylureas and other oral agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

Insulin sensitivity and its measurement: structural commonalities among the methods

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

Approach to lipoprotein management in 2001 National Cholesterol Guidelines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01258.X

21 January 2018

Identifiers

10.1111/J.1464-5491.2004.01258.X

1 reference

Europe PubMed Central

8 December 2017

1 reference

Europe PubMed Central

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44990830&oldid=2060685810"